During the corresponding time, Insulet Corporation recorded a revenue increase by 23.51 % year on year, sequentially revenue grew by 5.25 %. While revenue at the Insulet Corporation's corporate clients
Insulet's Comment on Sales, Marketing and Customers
The company serves customers primarily through wholesalers, healthcare organizations, pharmacies, and consumers in the United States. Coverage is provided by commercial insurance plans and government healthcare programs, including Medicare and Medicaid. The company negotiates reimbursement contracts with national and third-party payors and government agencies across all 50 states. Medicare Part D Plan Sponsors may cover Omnipod products under the Medicare Part D prescription drug program. Internationally, products are sold directly to consumers or through distributors, with reimbursement contracts established with local healthcare systems. Omnipod products are available in 25 countries, including the United States, Canada, Australia, the United Kingdom, Germany, France, and Italy. The company partners with Glooko Inc. for diabetes data management and has launched Omnipod Discover, a data analytics platform for users and healthcare providers to support diabetes management. The company maintains cybersecurity and information security certifications to ensure secure data transfer and storage.
In a landmark moment for diabetes management, Insulet Corporation (NASDAQ: PODD), a global leader in tubeless insulin pump technology, has announced that its Omnipod 5 Automated Insulin Delivery System (Omnipod 5) is now FDA-cleared for use by people with type 2 diabetes aged 18 and above. This marks it as the first and only Automated Insulin Delivery (AID) system to receive FDA clearance for both type 1 and type 2 diabetes management. This monumental advancement underscores Insulet s commitment to innovation and improving the quality of life for those managing diabetes. Additionally, the company has reported a significant financial uptick in the second quarter of 2024, further demonstrating its market domin...
Omnipod 5: A Revolution in Type 2 Diabetes Management Demonstrates Promising Clinical Outcomes and Improved Quality of Life ACTON, Mass. Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod brand of products, today unveiled groundbreaking results from its Omnipod 5 Automated Insulin Delivery System (Omnipod 5) pivotal trial for type 2 diabetes. The significant findings were presented at the American Diabetes Association (ADA) 84th Scientific Sessions in Orlando, Florida. This landmark study assessed the efficacy and safety of AID in a diverse cohort of individuals with type 2 diabetes, providing a new beacon of hope for improve...
Insulet Corporation, the global leader in tubeless insulin pump technology, has made significant advancements in the treatment of type 2 diabetes with its Omnipod 5 Automated Insulin Delivery System (Omnipod 5). The groundbreaking results from the pivotal trial of Omnipod 5 were shared at the American Diabetes Association s Scientific Sessions, showcasing its ability to improve clinical outcomes and enhance the quality of life for individuals with type 2 diabetes.The pivotal trial evaluated the impact of Automated Insulin Delivery (AID) in a diverse group of people with type 2 diabetes, demonstrating remarkable benefits. By leveraging innovative technology, Omnipod 5 allows for personalized and optimized ins...
In a significant leap towards responsible business growth, Insulet Corporation (NASDAQ: PODD), the dominant player behind revolutionary tubeless insulin pump technology marketed under the Omnipod brand, has recently published its landmark 2023 Sustainability Report. Crucially, the report underlines the corporation s unfettered commitment to continued sustainability efforts and product accessibility.A comprehensive review of this report reveals impressive strides made by Insulet in consolidating its environmental, social, and governance (ESG) initiatives throughout 2023. It is an upfront disclosure of their relentless pursuit of sustainability, a major driving force in generating substantial value for their s...
Insulet Corporation, the leading global provider of tubeless insulin pump technology, has recently released two significant updates regarding their Omnipod 5 Automated Insulin Delivery System (Omnipod 5). These groundbreaking developments include favorable results from a randomized controlled trial (RCT) and CE mark approval for compatibility with Abbott s FreeStyle Libre 2 Plus sensor. Let s delve into the facts and assess their impact on Insulet Corporation.Insulet s OP5-003 Trial Demonstrates Superiority:Insulet Corporation presented encouraging outcomes from its first-ever randomized controlled trial, known as the OP5-003 Trial. This clinical study focused on evaluating the effectiveness of the Omnipod 5...
Insulet to Present Results from First Omnipod 5 Randomized Controlled Trial (OP5-003) at the 17th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD)ACTON, Mass. - Insulet Corporation (NASDAQ: PODD), the global leader in tubeless insulin pump technology with its Omnipod brand of products, is set to present new clinical evidence at the 17th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD) in Florence, Italy from March 6 to 9, 2024. The presentation will focus on the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) and will be simultaneously available online.Insulet is excited to reveal the results of an important milestone in diabetes...
Insulet’s Comment on Sales, Marketing and Customers
The company serves customers primarily through wholesalers, healthcare organizations, pharmacies, and consumers in the United States. Coverage is provided by commercial insurance plans and government healthcare programs, including Medicare and Medicaid. The company negotiates reimbursement contracts with national and third-party payors and government agencies across all 50 states. Medicare Part D Plan Sponsors may cover Omnipod products under the Medicare Part D prescription drug program. Internationally, products are sold directly to consumers or through distributors, with reimbursement contracts established with local healthcare systems. Omnipod products are available in 25 countries, including the United States, Canada, Australia, the United Kingdom, Germany, France, and Italy. The company partners with Glooko Inc. for diabetes data management and has launched Omnipod Discover, a data analytics platform for users and healthcare providers to support diabetes management. The company maintains cybersecurity and information security certifications to ensure secure data transfer and storage.
Sources:
Insulet Corporation’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Insulet Corporation’s corporate clients.
For your research, we’ve provided 9 tables on Insulet Corporation corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
132.18 %